Maximum Dose of Unfractionated Heparin
There is no absolute maximum dose of unfractionated heparin specified in guidelines; dosing is weight-based and titrated to achieve therapeutic anticoagulation targets (aPTT 1.5-2.5 times control), with typical therapeutic infusion rates ranging from 18 units/kg/hour (approximately 30,000-40,000 units/24 hours for average-weight adults), though individual patients may require substantially higher or lower rates based on monitoring. 1, 2
Weight-Based Dosing for Therapeutic Anticoagulation
The standard approach uses weight-adjusted dosing rather than fixed maximum doses:
- Initial IV bolus: 80 units/kg 1, 3, 2
- Continuous infusion: 18 units/kg/hour 1, 3, 2
- Target aPTT: 1.5-2.5 times control (typically 45-75 seconds) 1, 3, 4, 2
For a 70 kg patient, this translates to approximately 30,000-40,000 units per 24 hours, but this is not a "maximum"—it is simply the typical requirement. 1, 2
Context-Specific Dosing Ranges
Cardiovascular Surgery
- Primary PCI without GP IIb/IIIa inhibitors: 100 units/kg bolus (or 70-100 units/kg) 4
- Primary PCI with GP IIb/IIIa inhibitors: 60 units/kg bolus 4
- Open-heart surgery: Not less than 150 units/kg, frequently 300 units/kg for procedures <60 minutes or 400 units/kg for procedures >60 minutes 2
Prophylactic Dosing (Low-Dose)
- Subcutaneous prophylaxis: 5,000 units every 8-12 hours 1, 2
- This fixed-dose regimen has a defined maximum, but therapeutic dosing does not 1, 2
Alternative Therapeutic Regimens
- Subcutaneous therapeutic: 333 units/kg initial dose, then 250 units/kg twice daily 1
- Intermittent IV: 10,000 units initial, then 5,000-10,000 units every 4-6 hours 2
Why No Absolute Maximum Exists
The dose is titrated to effect, not capped at a predetermined maximum. 1, 3, 2 Several factors explain this approach:
- Individual variability: Heparin exhibits nonlinear pharmacokinetics with saturable clearance mechanisms, meaning dose-response varies substantially between patients 1
- Monitoring-based adjustment: Doses are increased or decreased based on aPTT results every 4-6 hours until therapeutic range is achieved 1, 3, 2
- Clinical context matters: Patients with active thrombosis, obesity, or other factors may require higher doses per kilogram than standard protocols suggest 5, 6
Special Populations Requiring Dose Modifications
Morbidly Obese Patients
Morbidly obese patients require lower infusion rates per kilogram of actual body weight compared to normal-weight patients. 5, 6
- Mean infusion rate for therapeutic aPTT in class III obesity: 11.5 units/kg/hour (versus 13.5 units/kg/hour in normal-weight patients) 6
- Consider using adjusted body weight formulas: IBW + 0.3(ABW - IBW) or IBW + 0.4(ABW - IBW) 5
- Standard weight-based protocols with "maximum" initial rates can cause dangerous delays in achieving therapeutic anticoagulation in this population 5
Pediatric Patients
- Initial bolus: 75-100 units/kg IV over 10 minutes 2
- Maintenance infusion:
- Target aPTT: 60-85 seconds (reflecting anti-Factor Xa 0.35-0.70) 2
Renal Insufficiency
UFH is the preferred anticoagulant in severe renal dysfunction (CrCl <30 mL/min) because hepatic metabolism predominates over renal clearance. 1 No dose reduction is required for renal impairment. 1
Critical Monitoring and Dose Adjustment Protocol
Achieving therapeutic aPTT within 24 hours is associated with significantly lower mortality in pulmonary embolism. 3, 4 Use this standardized adjustment protocol:
| aPTT Result | Action |
|---|---|
| <35 seconds (<1.2× control) | Give 80 units/kg bolus; increase infusion by 4 units/kg/hour [3,4] |
| 35-45 seconds (1.2-1.5× control) | Give 40 units/kg bolus; increase infusion by 2 units/kg/hour [3,4] |
| 46-70 seconds (1.5-2.3× control) | No change [3,4] |
| 71-90 seconds (2.3-3.0× control) | Decrease infusion by 2 units/kg/hour [3,4] |
| >90 seconds (>3.0× control) | Stop infusion for 1 hour; reduce by 3 units/kg/hour [3,4] |
- First aPTT check: 4-6 hours after initial bolus 1, 3, 2
- Subsequent checks: Every 4-6 hours after dose changes, then daily once therapeutic 3, 2
- Additional monitoring: Platelet count (for HIT), hematocrit, occult blood in stool 2
Common Pitfalls and Safety Considerations
Fixed-Dose Protocols Are Dangerous
Using fixed doses (e.g., 5,000 unit bolus, 1,000 units/hour infusion) instead of weight-based dosing leads to excess dosing in low-weight patients and underdosing in heavier patients. 7
- 35% of patients receive excess weight-adjusted doses when fixed dosing is used 7
- Elderly and female patients are at highest risk for excess dosing due to lower body weight 7
- Excess bolus and infusion dosing is independently associated with increased major bleeding 7
Subtherapeutic Anticoagulation Increases Mortality
Failure to achieve therapeutic aPTT (>1.5× control) within 24 hours is associated with a 25% risk of recurrent venous thromboembolism. 8 Inadequate initial dosing or failure to adjust doses aggressively according to protocol is a critical error. 3
Duration and Overlap Requirements
- Minimum duration: 5 days of heparin therapy 3, 2, 8
- Warfarin overlap: Continue heparin for 4-5 days after starting warfarin, until INR ≥2.0 for at least 24 hours 1, 2, 8
- Do not taper: Discontinue heparin abruptly once therapeutic oral anticoagulation is achieved 2
Heparin-Induced Thrombocytopenia (HIT)
- Monitor platelet count: Once or twice weekly throughout therapy 9, 2
- Contraindication: UFH is contraindicated in active HIT 1
- Alternative agents: Use direct thrombin inhibitors or fondaparinux if HIT is suspected 1, 9
Bleeding Risk Management
The relationship between weight-adjusted UFH dose and major bleeding is proportional, with risk increasing substantially above recommended ranges (>70 units/kg bolus or >15 units/kg/hour infusion). 7 However, the risk of thrombosis from underdosing typically outweighs bleeding risk in acute thrombotic emergencies. 3